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CED can be deﬁned as temporary coverage for a novel health product
during collection of the additional evidence required to determine
whether deﬁnitive coverage is possible. The principle reﬁnements to
the scheme include a more precise deﬁnition of what may be
considered an innovative product, the possibility for device manufac-
turers to request CED either independently or in partnership with
hospitals, and the establishment of processing deadlines for health
authorities. In the long term, these modiﬁcations may increase the
number of applications to the CED scheme, which could lead toee front matter Copyright & 2016, International S
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ensure that the study conditions required by national health author-
ities are suitable for medical devices and that processing deadlines are
met for the scheme to be fully operational. Overall, the modiﬁcations
recently applied to the French CED scheme for innovative medical
devices should increase the transparency of the process, and therefore
be more appealing to medical device manufacturers.
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In all health care systems, coverage decisions tend to be based on
the best available evidence, with the aim of ensuring that
resources are judiciously allocated [1]. This may result, however,
in a binary “yes” or “no” approach that is biased against innovative
and promising technologies for which few clinical data are
available. This situation has applied to many innovative medical
devices released to market in the European Union. European
Union regulations concerning premarket evidence are currently
inadequate, and there is often a lack of appropriate data to support
the ability of new devices to respond to the expectations of
policymakers in the context of a reimbursement process [2,3].
In France, device manufacturers can request the health author-
ities to reimburse medical devices via two routes [4]. First,
reimbursement can be obtained if the characteristics of the device
match an existing generic deﬁnition on the list of devices qualify-
ing for reimbursement. In such cases, the manufacturer can
automatically register the device without the need for any addi-
tional evaluation by the national health authorities. The second
route available, particularly if the manufacturer is producing an
innovative product and wishes to charge a relatively high price, isto apply for reimbursement to the National Committee of Medical
Devices and Health Technologies (CNEDIMTS) [5]. This committee
initially assesses the expected clinical beneﬁt of the device to
determine whether it is sufﬁcient to merit reimbursement. It then
evaluates the added clinical value of the device in comparison
with existing technologies or alternative treatments [4,5]. In most
cases, too few data are available to accurately assess the expected
clinical beneﬁt. Consequently, more than half the applications
submitted to the CNEDIMTS each year are ﬁnally rejected or
withdrawn because of a lack of data [6].
Several countries including France have acted to prevent the
exclusion of promising technologies due to a lack of clinical
evidence, by introducing the Coverage with Evidence Develop-
ment (CED) scheme. This provides patients with provisional
access to a new device while the necessary evidence is acquired
to determine whether deﬁnitive coverage is warranted [1,7]. Five
years after the introduction of the CED scheme in France,
however, only two medical devices have beneﬁted: a high-
intensity focused ultrasound technique for treating prostate
cancer and a retinal prosthesis system to treat patients with
severe retinitis pigmentosa. In view of this relative failure, it was
generally agreed that there was a need to reform the CEDociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Conditions required for clinical or eco-
nomic studies submitted to obtain coverage with
evidence development in France.
Conditions required for the clinical/economic study
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medical devices in France. We then present the modiﬁcations
recently applied to this scheme by the French government.
Finally, we discuss the potential improvements following these
changes and the issues that remain unresolved.1. The study must be able to collect additional data required for
assessment of the expected clinical beneﬁt of the device. Studies
should be comparative unless there is either no relevant
comparator or for ethical reasons.
2. Ongoing studies with the device must be presented to assess the
relevance of the new study.
3. The feasibility of the study must be considered reasonable in
terms of both the protocol and the estimated budget.History of the French CED Scheme for Medical Devices
Conditional coverage for a new drug was ﬁrst tested in France in
2003 [8]. It was agreed that risperidone would be reimbursed
provided that the company performed studies to determine
whether it improved patient compliance. In 2007, the CNEDIMTS
proposed the creation of a CED scheme for innovative devices for
which the committee was unable to determine the expected
clinical beneﬁt. As part of the initial project, the manufacturer
was required to conduct a clinical trial on the basis of conditions
deﬁned by the CNEDIMTS itself. This early version of the scheme
was never implemented. Two years later, a new project was
launched, in Article L. 165-1-1 of the French Social Security Code
[9]. This article, in application since March 2010, laid down the
rules for a new evidence generation scheme for promising health
products or procedures. On the basis of technological intelligence
or applications for reimbursement, the CNEDIMTS could select
eligible innovative devices; however, device manufacturers were
not allowed to directly request the inclusion of their products in
the CED scheme. The committee would issue an expert opinion
that was then transmitted to the French Ministry of Health for a
ﬁnal decision. If the decision was positive, the Ministry of Health
subsequently deﬁned the conditions of the clinical trial. The
requirements covered the number of patients, indications for use,
funding period, and hospitals conducting the study. To our
knowledge, over the past 5 years, several medical devices have
been designated as eligible by the CNEDIMTS, in addition to the
two cited above, yet the Ministry of Health has neglected to make
any clear decisions. Consequently, a lack of innovative products
is not the result of the CED scheme failure, but perhaps a lack of
political will, possibly due to economic reasons.Recent Modiﬁcations to the French CED Scheme
In February 2015, a new decree came into force, modifying Article
L. 165-1-1 [10]. This decree deﬁnes four criteria that must be met
for a new device to be considered innovative: 1) the medical
device must be novel and not simply an updated version of an
existing product used for the same indications; 2) the medical
device must only recently have become available on the market
and not have been previously reimbursed by the French national
health insurance agency for the indications concerned; 3) the
available clinical data for the product must have clearly estab-
lished the potential risks for patients and users; 4) the available
clinical and/or economic data must have shown that the product
is likely to a) provide signiﬁcant clinical beneﬁt for an unmet or
insufﬁciently covered medical need or b) decrease health care
expenditure due to its cost-effectiveness, although only if the
device is at least as effective as the standard treatment.
Device manufacturers can now apply directly for the inclusion
of their products in the CED program, either independently or in
partnership with a hospital. For eligibility, applicants must
submit a clinical or economic study project plan that meets three
essential conditions (see Table 1). The application is still sub-
mitted to the CNEDIMTS for assessment, as well as simultane-
ously being submitted to the Ministry of Health. In addition to the
study project, the applicant is asked to estimate the budget
required to carry out the study and must make a formal commit-
ment to provide the national health authorities with full access tothe data collected. The decree speciﬁes that the study data can be
used by the Economic Committee for Health Products & Services
(Comité Economique des Produits de Santé [CEPS]) during future price
negotiations.
Finally, the decree introduces processing deadlines. The
CNEDIMTS now has a maximum of 45 days to check the
completeness of the submission and deliver an opinion on the
admissibility of the application. The commission subsequently
has a maximum of 30 days to conﬁrm the suitability of the
proposed study for the collection of additional data required to
determine the expected clinical beneﬁt of the product. The
duration of the study and the number of patients to be included
must also be validated. At the same time, the Ministry of Health
determines whether the estimated budget is reasonable. Once
both assessments have been completed, the Ministry of Health
must conﬁrm its ﬁnal decision within 30 days. Finally, the
funding required for the study is provided entirely by the French
national health insurance agency.Improvements and Unresolved Issues
In a previous study, we concluded that improvements to the
French CED scheme were required to ensure that the process is
fully operational [11]. The recent modiﬁcations have partly
resolved the issues we raised. First, the transparency of the
process has increased, by setting criteria that clearly deﬁne an
innovative device. Before the new decree, it was left entirely to
the CNEDIMTS to determine whether a new product could be
considered innovative. In addition, device manufacturers can
now directly request the inclusion of their products in the CED
scheme, as is already the case in other countries, such as
Germany [12]. These modiﬁcations will probably have a major
impact on the market access strategies of medical device com-
panies, who will now consider this coverage option for their
products. The French CED scheme is also potentially appealing to
device manufacturers because full funding is offered and the
reimbursement of study expenses is not requested even if results
do not provide conclusive evidence. This is a major strength of
the scheme because the collection of supplementary evidence
can often result in the manufacturer making a loss in other
countries [13,14]. We believe that the French CED scheme offers a
great opportunity for small- and medium-sized enterprises
(SMEs) with insufﬁcient resources to manage large-scale clinical
trials. In France, where 94% of medical device companies are
SMEs, the new CED scheme can be regarded as a major support to
innovation in this sector, in addition to the research and
innovation tax credit recently implemented. In addition, the data
collected can be reused in other countries for future reimburse-
ment applications or ﬁnding new markets. From the point of view
of health care providers, the scheme is likely to improve access to
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excessive ﬁnancial risk for devices with little available evidence.
The funding of CED projects, however, may become a critical
issue in the long term if the number of applications signiﬁcantly
increases. Therefore, substantial and sustainable funding for
future studies will be required, particularly if high-quality evi-
dence is to be obtained [15]. To date, the Ministry of Health has not
indicated how many CED projects will be annually funded or
whether a maximum budget will be set. Furthermore, the CNE-
DIMTS and the Ministry of Health will need to devote additional
resources to ensure an adequate follow-up of all CED projects.
The possible involvement of hospitals in the scheme is a
positive aspect. The early involvement of clinical investigators is
likely to favor the successful establishment of future projects.
Indeed, French hospitals have experience in hospital-based
research programs funded by the Ministry of Health for non-
reimbursed innovative devices, which are successful largely due
to the involvement of the end users [11]. Partnerships with
hospitals are also desirable for SMEs as they frequently require
guidance in the design of clinical trials, which is increasingly
offered by French university hospitals [16]. However, although
randomised controlled trials are considered to be the gold stand-
ard for decision-making, the use of a randomised design is not
always feasible for medical devices [14,17]. This standard is
difﬁcult to achieve with medical devices, for many reasons,
including “learning curve” issues, frequent product modiﬁca-
tions, and difﬁculties enrolling patients [18,19]. The French
national health authorities should therefore consider alternative
methods better suited to medical devices, such as Bayesian
methods or tracker studies [20,21].
Finally, the new processing deadlines for the CNEDIMTS and
the Ministry of Health should reduce bureaucratic delays, which
were perceived as too long by device manufacturers. This will
ensure that the process is completed in a more timely and
transparent manner. Other countries have recently reformed their
CED schemes, with the introduction of faster processing times,
such as in the United Kingdom [22]. Nevertheless, the decree does
not state whether the time frame will be also limited for pricing
negotiations with the CEPS at the end of the study. In addition, the
decree does not declare whether the manufacturer can expect a
“premium” price on the basis of additional evidence generated and
how these data can affect the CEPS price decisions. The primary
intent of the scheme, however, is to provide as much evidence as
possible to the CNEDIMTS to establish the added clinical value of
the device. The CEPS decisions are then largely based on the
conclusions made by the CNEDIMTS, which is potentially very
positive provided that most uncertainties have been removed.
In conclusion, we feel that the recent modiﬁcations to the
French CED scheme for innovative medical devices represent a
step in the right direction, particularly with respect to greater
transparency. The scheme now shares many features with other
CED schemes worldwide. As recently stated by Olberg et al. [12],
there may be an emerging international standard for CED [12]. It
remains to be seen, however, how CED projects will be funded in
the long term, how hospital partnerships will be set up, whether
national health authorities will consider alternative study meth-
ods, and whether the new processing deadlines will be met.Source of ﬁnancial support: The authors have no other
ﬁnancial relationships to disclose.
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